Department of Critical Care Medicine, Shanghai East Hospital, Shanghai, 200120, China.
Department of Cardiovascular Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
J Cardiothorac Surg. 2023 Apr 17;18(1):154. doi: 10.1186/s13019-023-02253-x.
To evaluate the effect of preoperative pulmonary artery pressure on perioperative outcome of end-stage heart failure patients undergoing heart transplantation.
Retrospective analysis was undertaken on the clinical data of patients receiving heart transplantation in the Department of Cardiovascular Surgery of our hospital from March 2017 to March 2022. A ROC curve analysis was developed between mean pulmonary artery pressure (mPAP) and postoperative mortality using mPAP as diagnostic criteria. Patients were divided into groups based on this threshold to determine the best mPAP threshold value for predicting postoperative nosocomial mortality, and the differences in preoperative and intraoperative data, postoperative complications, and clinical prognosis of patients in the two groups were compared. Patients were followed up to draw the survival curve of patients in the two groups.
The study enlisted the participation of 105 patients. ROC curve research revealed that preoperative pulmonary artery pressure was substantially linked with death following heart transplantation, with mPAP = 30.5mmHg being the best threshold. The group with mPAP ≥ 30.5mmHg had a greater incidence of postoperative ECMO support (28.2% vs. 10.6%, P = 0.021) and a higher incidence of in-hospital mortality (15.4% vs. 1.5%, P = 0.019) than the group with mPAP < 30.5mmHg. The postoperative survival rates of 105 patients were 91.3%, 88.7%, 81.6%, and 77.5% at 1, 2, 3, and 4 years, respectively, however, there was no significant difference between the two groups of patients in the postoperative intermediate-far survival rate (P = 0.431).
Preoperative pulmonary artery pressure in patients with end-stage heart failure is intimately correlated with perioperative prognosis of heart transplant recipients. The optimal cut-off mPAP value in predicting perioperative prognosis of heart transplant recipients is 30.5mmHg. In the high mPAP group, perioperative ECMO support rate and perioperative mortality rate are high, which do not affect the medium and long-term prognosis of the recipients undergoing heart transplantation.
评估终末期心力衰竭患者接受心脏移植时术前肺动脉压对围手术期结局的影响。
对 2017 年 3 月至 2022 年 3 月我院心血管外科接受心脏移植的患者的临床资料进行回顾性分析。采用受试者工作特征(ROC)曲线分析平均肺动脉压(mPAP)与术后死亡率的关系,以 mPAP 为诊断标准。根据该阈值将患者分为两组,以确定预测术后院内死亡率的最佳 mPAP 阈值,并比较两组患者术前和术中数据、术后并发症和临床预后的差异。对患者进行随访,绘制两组患者的生存曲线。
本研究共纳入 105 例患者。ROC 曲线研究表明,术前肺动脉压与心脏移植后死亡密切相关,mPAP=30.5mmHg 为最佳阈值。mPAP≥30.5mmHg 组术后使用体外膜肺氧合(ECMO)支持的发生率(28.2%比 10.6%,P=0.021)和院内死亡率(15.4%比 1.5%,P=0.019)均高于 mPAP<30.5mmHg 组。105 例患者的术后 1、2、3、4 年生存率分别为 91.3%、88.7%、81.6%和 77.5%,但两组患者的术后中远期生存率差异无统计学意义(P=0.431)。
终末期心力衰竭患者术前肺动脉压与心脏移植受者围手术期预后密切相关。预测心脏移植受者围手术期预后的最佳 mPAP 截断值为 30.5mmHg。在 mPAP 较高的组中,围手术期 ECMO 支持率和围手术期死亡率较高,但不影响接受心脏移植的受者的中远期预后。